AR049487A1 - Compuestos de imidazol sustituidos - Google Patents
Compuestos de imidazol sustituidosInfo
- Publication number
- AR049487A1 AR049487A1 ARP050101299A ARP050101299A AR049487A1 AR 049487 A1 AR049487 A1 AR 049487A1 AR P050101299 A ARP050101299 A AR P050101299A AR P050101299 A ARP050101299 A AR P050101299A AR 049487 A1 AR049487 A1 AR 049487A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- alkyl
- groups
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- -1 trifluoromethylthio, difluoromethoxy Chemical group 0.000 abstract 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000005968 oxazolinyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de imidazol sustituidos y procesos para preparar ese tipo de compuestos, su utilizacion en el tratamiento de la obesidad, trastornos psiquiátricos y neurologicos, a métodos para su utilizacion terapéutica y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1) y sus sales aceptables para uso farmacéutico, en la cual R1 representa a) un grupo alcoxi C1-10 opcionalmente sustituido con uno o más F; b) un grupo de formula fenil(CH2)pO- en la cual p es 1, 2 o 3 y el anillo de fenilo está opcionalmente sustituido con 1, 2 o 3 grupos representados por Z; c) un grupo R5S(O)2O o R5S(O)2NH donde R5 representa un grupo alquilo C1-10 opcionalmente sustituido con uno o más F, o R5 representa fenilo o un grupo heteroarilo cada uno de los cuales está opcionalmente sustituido con 1, 2 o 3 grupos representados por Z o d) un grupo de la formula (R6)3Si en la cual R6 representa un grupo alquilo C1-6 el cual puede ser igual o diferente; Ra representa halo, un grupo alquilo C1-3 o un grupo alcoxi C1-3; m es 0, 1, 2 o 3; R2 representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, nitro, ciano o halo; n es 0, 1, 2 o 3; R3 representa a) un grupo X-Y-NR7R8, en la cual X es CO o SO2, Y está ausente o representa NH opcionalmente sustituido con un grupo alquilo C1-3; y R7 y R8 representan independientemente: un grupo alquilo C1-6 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo cicloalquilo C3-15 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo (cicloalquil C3-15)alquileno C1-3 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo -(CH2)r(fenilo)s en el cual r es 0, 1, 2, 3 o 4, s es 1 cuando r es 0 de otro modo s es 1 o 2 y los grupos fenilo están sustituidos opcionalmente en forma independiente con uno, dos o tres grupos representados por Z; un grupo heterocíclico de 5 a 8 miembros saturado que contiene un N y opcionalmente uno de los siguientes: O, S o un N adicional donde el grupo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-3, hidroxi o bencilo; un grupo -(CH2)tHet en el cual t es 0, 1, 2, 3 o 4, y la cadena alquileno está opcionalmente sustituida con uno o más grupos alquilo C1-3 y Het representa un grupo heteroarilo opcionalmente sustituido con 1, 2 o 3 grupos seleccionados de un grupo alquilo C1-5, un grupo alcoxi C1-5 o halo donde el grupo alquilo y alcoxi están opcionalmente sustituidos en forma independiente con 1 o más F; o R7 representa H y R8 es segun lo definido anteriormente; o R7 y R8 junto con el átomo de N al cual están unidos representan un grupo heterocíclico de 5 a 8 miembros saturado o parcialmente insaturado que contiene un N y opcionalmente uno de los siguientes: O, S o un N adicional, donde el grupo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-3, hidroxi, F o bencilo; o b) oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo, tienilo, furilo u oxazolinilo, cada uno opcionalmente sustituido con 1, 2 o 3 grupos Z; R4 representa H, un grupo alquilo C1-6, un grupo alcoxi C1- 6 o un grupo alcoxi C1-6-alquileno C1-6 el cual contiene un máximo de 6 átomos de C, cada uno de estos grupos está opcionalmente sustituido con uno o más F o ciano; Z representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, halo, trifluormetilo, trifluormetiltio, difluormetoxi, trifluormetilsulfonilo, nitro, amino, mono o dialquilamino C1-3, alquilsulfonilo C1-3, alcoxicarbonilo C1-3, carboxi, ciano, carbamoílo, mono o dialquilcarbamoílo C1-3 y acetilo y W representa hidroxi, F, un grupo alquilo C1-3, un grupo alcoxi C1-3, amino, mono o dialquilamino C1-3 o una amina heterocíclica seleccionada entre morfolinilo, pirrolidinilo, piperidinilo o piperazinilo donde la amina heterocíclica está opcionalmente sustituida con un grupo alquilo C1-3 o hidroxilo; con la condicion de que cuando n es 1 entonces R2 no es metoxi en la posicion 2 o la posicion 4 del anillo de fenilo y con la condicion adicional de que R1 no es metilsulfonilamino, metoxi o CF3O-.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407671A GB0407671D0 (en) | 2004-04-03 | 2004-04-03 | Therapeutic agents |
| GB0420781A GB0420781D0 (en) | 2004-09-18 | 2004-09-18 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049487A1 true AR049487A1 (es) | 2006-08-09 |
Family
ID=34963354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101299A AR049487A1 (es) | 2004-04-03 | 2005-04-01 | Compuestos de imidazol sustituidos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7799804B2 (es) |
| EP (1) | EP1735287A1 (es) |
| JP (1) | JP4177435B2 (es) |
| KR (1) | KR20060133084A (es) |
| AR (1) | AR049487A1 (es) |
| AU (1) | AU2005229459B9 (es) |
| BR (1) | BRPI0509515A (es) |
| CA (1) | CA2560417C (es) |
| IL (1) | IL178427A0 (es) |
| NO (1) | NO20064974L (es) |
| RU (1) | RU2377238C2 (es) |
| TW (1) | TW200539872A (es) |
| UY (1) | UY28839A1 (es) |
| WO (1) | WO2005095354A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6526575B1 (en) | 1997-01-07 | 2003-02-25 | United Video Properties, Inc. | System and method for distributing and broadcasting multimedia |
| AR054417A1 (es) * | 2004-12-23 | 2007-06-27 | Astrazeneca Ab | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. |
| GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
| GB0518819D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
| AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| DE602007007594D1 (de) * | 2006-04-14 | 2010-08-19 | Merck Sharp & Dohme | Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren |
| AU2007238804A1 (en) | 2006-04-14 | 2007-10-25 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
| US7795265B2 (en) | 2006-04-14 | 2010-09-14 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
| WO2008091631A1 (en) | 2007-01-26 | 2008-07-31 | Merck & Co., Inc. | Substituted aminopyrimidines as cholecystokinin-1 receptor modulators |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| CN110403942A (zh) | 2007-04-11 | 2019-11-05 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
| WO2014199164A1 (en) * | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE140966C (es) | ||||
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| SE9302333D0 (sv) * | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| PT1268435E (pt) | 2000-03-23 | 2007-02-28 | Solvay Pharm Bv | Derivados de 4,5-diidro-1h-pirazol tendo actividade cb1-antagonista |
| AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| PE20030547A1 (es) * | 2001-09-24 | 2003-08-18 | Bayer Corp | Derivados de imidazol para el tratamiento de la obesidad |
| US20040248956A1 (en) * | 2002-01-29 | 2004-12-09 | Hagmann William K | Substituted imidazoles as cannabinoid receptor modulators |
| CA2476594C (en) | 2002-03-05 | 2012-10-09 | Transtech Pharma, Inc. | Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| US6799511B2 (en) * | 2002-12-03 | 2004-10-05 | Day International, Inc. | Gapless compressible cylinder assembly |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| ATE450505T1 (de) | 2003-01-02 | 2009-12-15 | Hoffmann La Roche | Cb 1 rezeptor inversagonisten |
| WO2004099130A2 (en) | 2003-05-08 | 2004-11-18 | Astellas Pharma Inc. | 1,2-diarylimidazoles useful as inhibitors of cox |
-
2005
- 2005-03-30 JP JP2007505623A patent/JP4177435B2/ja not_active Expired - Fee Related
- 2005-03-30 CA CA2560417A patent/CA2560417C/en not_active Expired - Fee Related
- 2005-03-30 KR KR1020067023116A patent/KR20060133084A/ko not_active Ceased
- 2005-03-30 AU AU2005229459A patent/AU2005229459B9/en not_active Ceased
- 2005-03-30 BR BRPI0509515-8A patent/BRPI0509515A/pt not_active IP Right Cessation
- 2005-03-30 EP EP05729088A patent/EP1735287A1/en not_active Withdrawn
- 2005-03-30 WO PCT/GB2005/001153 patent/WO2005095354A1/en not_active Ceased
- 2005-03-30 RU RU2006135482/04A patent/RU2377238C2/ru not_active IP Right Cessation
- 2005-03-30 US US11/547,048 patent/US7799804B2/en not_active Expired - Fee Related
- 2005-04-01 AR ARP050101299A patent/AR049487A1/es not_active Application Discontinuation
- 2005-04-01 UY UY28839A patent/UY28839A1/es unknown
- 2005-04-01 TW TW094110566A patent/TW200539872A/zh unknown
-
2006
- 2006-10-03 IL IL178427A patent/IL178427A0/en unknown
- 2006-10-31 NO NO20064974A patent/NO20064974L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2560417C (en) | 2011-04-19 |
| IL178427A0 (en) | 2007-02-11 |
| RU2377238C2 (ru) | 2009-12-27 |
| US20070208059A1 (en) | 2007-09-06 |
| US7799804B2 (en) | 2010-09-21 |
| JP4177435B2 (ja) | 2008-11-05 |
| JP2007531723A (ja) | 2007-11-08 |
| AU2005229459A1 (en) | 2005-10-13 |
| RU2006135482A (ru) | 2008-05-10 |
| UY28839A1 (es) | 2005-11-30 |
| EP1735287A1 (en) | 2006-12-27 |
| AU2005229459B2 (en) | 2008-09-25 |
| NO20064974L (no) | 2006-10-31 |
| CA2560417A1 (en) | 2005-10-13 |
| AU2005229459B9 (en) | 2009-01-22 |
| KR20060133084A (ko) | 2006-12-22 |
| WO2005095354A1 (en) | 2005-10-13 |
| TW200539872A (en) | 2005-12-16 |
| BRPI0509515A (pt) | 2007-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047683A1 (es) | Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos | |
| AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
| AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
| AR054417A1 (es) | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. | |
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| AR049487A1 (es) | Compuestos de imidazol sustituidos | |
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
| UY28374A1 (es) | Agentes terapéuticos | |
| AR063625A1 (es) | COMPUESTOS HETEROCICLICOS eTILES COMO AGENTES ANTICANCEROSOS | |
| BRPI0810929B8 (pt) | uso de um composto de fórmula 1 | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| MY141255A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| JO2741B1 (en) | Spiro-cyclic nitroblast as protease inhibitors | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
| EA200702469A1 (ru) | Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов | |
| WO2006136837A3 (en) | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |